SCHEMBL20738465

SCHEMBL20738465

CC(C)Oc1ccc(C(C)CO)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB11 O95342 1/20 0.53
POLB P06746 1/20 0.47
KMT2A Q03164 3/20 0.47
PARP10 Q53GL7 1/20 0.46
CNR2 P34972 1/20 0.44
ALDH1A3 P47895 1/20 0.44
MEN1 O00255 1/20 0.42
MITF O75030 1/20 0.42
CYP1A2 P05177 1/20 0.42
GAA P10253 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C19 P33261 1/20 0.42
GLA P06280 1/20 0.42
ALDH1A1 P00352 4/20 0.41
ACACB O00763 3/20 0.41
MAPT P10636 2/20 0.41
NLRP1 Q9C000 1/20 0.41
ACACA Q13085 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6680649 0.83 ABCB11 (0.56) ABCB11KMT2AMEN1GAAALDH1A1
SCHEMBL2641075 0.82 ABCB11 (0.52) ABCB11
SCHEMBL12438456 0.81 ALDH1A1 (0.53) POLBKMT2APARP10CNR2ALDH1A3
SCHEMBL7419755 0.81 ABCB11 (0.70) ABCB11KMT2AMEN1CYP1A2GAA
SCHEMBL7051522 0.81 ABCB11 (0.70) ABCB11KMT2AMEN1CYP1A2GAA
SCHEMBL8512107 0.80 PARP10 (0.47) POLBKMT2APARP10CNR2ALDH1A3
SCHEMBL8512103 0.80 PARP10 (0.47) POLBKMT2APARP10CNR2ALDH1A3
SCHEMBL22435579 0.78 ALDH1A3 (0.42) POLBKMT2APARP10CNR2ALDH1A3
SCHEMBL1416955 0.77 ABCB11 (0.47) ABCB11KMT2AMEN1GAAALDH1A1
SCHEMBL9570590 0.77 PTPN5 (0.43) POLBKMT2APARP10CNR2ALDH1A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230019032-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2023-01-19 US disclosed
US-11001575-B1 Benzolactam compounds as protein kinase inhibitors OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2021-05-11 US disclosed
US-10457669-B2 Benzolactam compounds as protein kinase inhibitors OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2019-10-29 US disclosed
US-20190047990-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2019-02-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230019032-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS MAPK1, ALK, MAP3K1 ABCB11 2337/4885POLB 2980/4885KMT2A 968/4885
US-20190047990-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS MAPK1, ALK, MAP3K1 ABCB11 2337/4885POLB 2980/4885KMT2A 968/4885
US-11001575-B1 Benzolactam compounds as protein kinase inhibitors MAPK1, ALK, MAP3K1 ABCB11 2454/4885POLB 2983/4885KMT2A 997/4885
US-10457669-B2 Benzolactam compounds as protein kinase inhibitors MAPK1, ALK, MAP3K1 ABCB11 2337/4885POLB 2980/4885KMT2A 968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.